公开(公告)号：US11981747B1

公开(公告)日：2024-05-14

申请号：US18365828

申请日：2023-08-04

Applicant: ONO PHARMACEUTICAL CO., LTD. ,  TOHOKU UNIVERSITY

Inventor： Yukinari Kato ,  Mika Kaneko ,  Daisuke Nakayama ,  Masayuki Kurogi

IPC: C07K16/32

CPC classification number: C07K16/32 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/92

Abstract: An antibody or antigen-binding fragment thereof is disclosed. The antibody or antigen-binding fragment thereof binds to HER2 expressed on a cancer cell or a fragment of the HER2. A HER2-targeting agent containing any of the antibody or antigen-binding fragment thereof, and a pharmaceutical composition containing the HER2-targeting agent are disclosed.

公开(公告)号：US11306152B2

公开(公告)日：2022-04-19

申请号：US16498411

申请日：2017-03-30

Applicant: Tohoku University ,  Zenogen Pharma Co., Ltd.

Inventor： Yukinari Kato ,  Mika Kato ,  Shinji Yamada ,  Satoshi Ogasawara ,  Takuro Nakamura

IPC: C07K16/30 ,  A61K39/00

Abstract: The present invention provides a cancer cell-specific anti-podoplanin antibody or an antigen-binding fragment thereof having an epitope in a Thr85-containing region of an amino acid sequence of human podoplanin represented by SEQ ID NO: 1, the Thr85 having a sialylated O-glycan added thereto.

公开(公告)号：US20190211108A1

公开(公告)日：2019-07-11

申请号：US16088941

申请日：2016-03-31

Applicant: Tohoku University

Inventor： Yukinari Kato ,  Mika Kato ,  Satoshi Ogasawara

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2896 ,  A61K39/395 ,  A61P35/00 ,  C07K16/32 ,  C07K2317/41 ,  C12N5/10 ,  C12N15/09

Abstract: The present invention provides a cancer microenvironment-targeting anti-podocalyxin antibody or antigen binding fragment thereof.

公开(公告)号：US11046778B2

公开(公告)日：2021-06-29

申请号：US16088941

申请日：2016-03-31

Applicant: Tohoku University ,  ZENOAQ RESOURCE CO., LTD.

Inventor： Yukinari Kato ,  Mika Kato ,  Satoshi Ogasawara

IPC: A61K39/00 ,  C07K16/28 ,  C12N5/10 ,  C12N15/09 ,  C07K16/32 ,  A61K39/395 ,  A61P35/00

Abstract: The present invention provides a cancer microenvironment-targeting anti-podocalyxin antibody or antigen binding fragment thereof.

公开(公告)号：US20210115151A1

公开(公告)日：2021-04-22

申请号：US16498411

申请日：2017-03-30

Applicant: Tohoku University ,  ZENOAQ RESOURCE CO., LTD.

Inventor： Yukinari Kato ,  Mika Kato ,  Shinji Yamada ,  Satoshi Ogasawara ,  Takuro Nakamura

IPC: C07K16/30

Abstract: The present invention provides a cancer cell-specific anti-podoplanin antibody or an antigen-binding fragment thereof having an epitope in a Thr85-containing region of an amino acid sequence of human podoplanin represented by SEQ ID NO: 1, the Thr85 having a sialylated O-glycan added thereto.

公开(公告)号：US20180134786A1

公开(公告)日：2018-05-17

申请号：US15549923

申请日：2016-02-12

Applicant: Tohoku University

Inventor： Yukinari Kato ,  Mika Kaneko ,  Satoshi Ogasawara

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  G01N33/574

CPC classification number: C07K16/28 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2896 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C12N5/10 ,  C12N15/02 ,  C12N15/09 ,  G01N33/574 ,  G01N33/57492 ,  G01N2333/705

Abstract: The present invention provides a method for producing an antibody against podocalyxin expressed specifically in cancer cells. The method includes a step of introducing a nucleic acid encoding all or a portion of podocalyxin into cells expressing a cancer cell-specific sugar chain structure to cause cancer cell-specific podocalyxin or a portion thereof to be expressed therein, a step of immunizing a non-human mammal with the cancer cell-specific podocalyxin or portion thereof to obtain antibodies, and a step of purifying the antibodies by primary screening using purified cancer cell-specific podocalyxin or a portion thereof.

公开(公告)号：US10906972B2

公开(公告)日：2021-02-02

申请号：US15549923

申请日：2016-02-12

Applicant: Tohoku University ,  ZENOAQ RESOURCE CO., LTD.

Inventor： Yukinari Kato ,  Mika Kaneko ,  Satoshi Ogasawara

IPC: C07K16/28 ,  C12N5/10 ,  G01N33/574 ,  C12N15/09 ,  C07K16/30 ,  A61P35/00 ,  A61K39/00 ,  C12N15/02

Abstract: The present invention provides a method for producing an antibody against podocalyxin expressed specifically in cancer cells. The method includes a step of introducing a nucleic acid encoding all or a portion of podocalyxin into cells expressing a cancer cell-specific sugar chain structure to cause cancer cell-specific podocalyxin or a portion thereof to be expressed therein, a step of immunizing a non-human mammal with the cancer cell-specific podocalyxin or portion thereof to obtain antibodies, and a step of purifying the antibodies by primary screening using purified cancer cell-specific podocalyxin or a portion thereof.